Company: PRME
Filing Date: 2025-05-19
Form Type: 8-K
Source: 0001193125-25-122156
Chunk: 3

Company: Prime Medicine, Inc.
Filing Date: 2025-05-19
Form: 8-K
Item: Item 5.02
Chunk 3
---
 Control,” if higher), in each case subject to reductions by any amount received by him pursuant to a restrictive covenant agreement, (ii) subject to Dr. Reine’s co-paymentof premium amounts at the applicable active employees’ rate and proper election to continue COBRA health coverage, payment of the portion of the premium equal to the amount the Company would have paid to provide health insurance had he remained employed by us until the earliest of (A) eighteen (18) months from the date of his separation, (B) his eligibility for group medical plan benefits under any other employer’s group medical plan or (C) the end of his COBRA health continuation period, and (iii) the bonus amount (if any) that Dr. Reine would have been paid if he had remained employed through the payment date, if such termination occurs on or after January 1 but before the date bonuses are paid for the prior year to the Company’s other executives. In addition, in the event Dr. Reine is terminated by us without cause or he resigns for good reason, in each case within eighteen (18) months following a “ Change in Control,” all of the then-outstanding and unvested portion of his stock options and other stock-based awards that are subject solely to time-based vesting shall become fully vested and exercisable or non-forfeitableimmediately as of the date of termination, with any such performance-based awards vesting at target.

Pursuant to the Reine Employment Agreement, the Board approved the grant of a stock option to purchase up to 2,000,000 shares of the Company’s common stock, par value $0.00001 per share (“ Common Stock”), pursuant to the Company’s 2022 Stock Option and Incentive Plan (the “2022 Plan”) to Dr. Reine. The stock option award will have an exercise price equal to the closing price of the Company’s common stock on the Nasdaq Global Market on the date of grant. Twenty-five percent of the shares will vest on the one-yearanniversary of the date of the grant and the balance will vest monthly in equal installments over the following thirty-six(36) months, subject to Dr. Reine’s continuous service. In addition, the Board approved the grant of a stock option to purchase up to 500,000 shares of Common Stock pursuant to the Plan to Dr. Reine. The stock option award will have an exercise price equal to the closing price of Common Stock on the Nasdaq Global Market on